EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection

Jennifer Audsley iD, Anchalee Avihingsanon iD, Xin Li, Rosalind Edwards iD, Kathy Jackson, Nadia Warner, Olivia Maslac, Peter A Revill, Hay Mar Su Lwin iD, Sivaporn Gatechompol iD, Nagalingeswaran Kumarasamy, Tim Spelman und 4 weitere

Clinical Infectious Diseases · 09.02.2026 · 82 (1) · e176-e184

DOI: 10.1093/cid/ciaf281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 31.05.2025. Verfasst von Jennifer Audsley und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, HIV Infections, Hepatitis B, Chronic, Coinfection. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHMRC, APP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

An effective therapeutic strategy for hepatis B virus (HBV) cure remains an urgent unmet need. We aimed to define the incidence, kinetics, and predictors of hepatitis B surface antigen (HBsAg) loss in people with HIV and HBV (PWH-HBV) following HBV-active antiretroviral therapy (ART) in PWH-HBV in Asia.

Methods

97 PWH-HBV commencing HBV-active ART were recruited prospectively in Thailand (n = 94) and Malaysia (n = 3), then followed for 24 months. Time to HBV serology change was calculated. Univariate associations between baseline characteristics and HBsAg loss were examined using the Mann-Whitney or chi-square tests. Multivariable analysis was undertaken using Cox regression.

Results

Twenty-one individuals (22%) lost HBsAg during follow-up (11.7 per 100 person-years), 14 of whom gained anti-HBs. Twenty-two of 61 (36.1%) individuals who were hepatitis B “e” antigen (HBeAg) positive at baseline lost HBeAg over the study, 15 of whom gained anti-HBe. Most individuals lost HBsAg and HBeAg by the month 12 study visit (81% and 63.6%, respectively), with median times of 5.8 and 12.0 months to HBsAg and HBeAg loss, respectively. Univariate analysis showed baseline characteristics associated with HBsAg loss were higher alanine aminotransferase (ALT; P = .005), tenofovir alafenamide (TAF)–containing ART regimen (P = .025), younger age (P = .040), lower liver stiffness (P = .010), and quantitative HBsAg < log10 2.0 IU/mL (P = .001). All 5 factors remained significant in a Cox regression analysis that adjusted for baseline CD4 count.

Conclusions

High HBsAg loss rates occur in PWH and HBV early after commencing ART. Our study suggests that TAF-containing ART regimens may be preferable as first-line therapy in HIV-HBV coinfection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Surface AntigensHIV InfectionsHepatitis B, ChronicCoinfectionHumansMaleFemaleAdultThailandMalaysiaMiddle AgedProspective StudiesAntiviral AgentsHepatitis B e AntigensHepatitis B virusAntiretroviral Therapy, Highly ActiveTenofovir

Stichwörter der Autor:innen

HBsAg lossHIV-HBV coinfectionantiretroviral therapytenofovir alafenamidetreatment initiation

Substanzen

Hepatitis B Surface AntigensAntiviral AgentsHepatitis B e AntigensTenofovir

Autor:innen und Institutionen

  • Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS and Infectious Diseases Research Centre (AIDSID), and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn Uni…
  • Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
  • Infectious Diseases Medical Centre, Voluntary Health Services Hospital, Chennai, India.
  • Public Health, Burnet Institute, Melbourne, Australia.
  • Department of Medicine, University of Adelaide, Adelaide, Australia.

ORCID-Profile: Jennifer Audsley, Anchalee Avihingsanon, Rosalind Edwards, Hay Mar Su Lwin, Sivaporn Gatechompol

Förderung

  • NHMRC
  • APP

Zitieren

APA

Audsley, J., Avihingsanon, A., Li, X., Edwards, R., Jackson, K., Warner, N., Maslac, O., Revill, P. A., Lwin, H. M. S., Gatechompol, S., Kumarasamy, N., Spelman, T., Azwa, I., Kamarulzaman, A., Lewin, S. R., & Sasadeusz, J. (2026). Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection. Clinical Infectious Diseases, 82(1), e176-e184. https://doi.org/10.1093/cid/ciaf281

Vancouver

Audsley J, Avihingsanon A, Li X, Edwards R, Jackson K, Warner N, et al. Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection. Clinical Infectious Diseases. 2026;82(1):e176-e184. doi:10.1093/cid/ciaf281

BibTeX
@article{Audsley2026,
  author = {Audsley, Jennifer and Avihingsanon, Anchalee and Li, Xin and Edwards, Rosalind and Jackson, Kathy and Warner, Nadia and Maslac, Olivia and Revill, Peter A and Lwin, Hay Mar Su and Gatechompol, Sivaporn and Kumarasamy, Nagalingeswaran and Spelman, Tim and Azwa, Iskandar and Kamarulzaman, Adeeba and Lewin, Sharon R and Sasadeusz, Joe},
  title = {Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {1},
  pages = {e176--e184},
  doi = {10.1093/cid/ciaf281}
}
Kostenlos starten →